About Me
I was first drawn to medicine because I wanted to help people. I chose hematology and oncology because they are rapidly evolving fields—through their advances, I can treat people using the newest therapies. More importantly, I can care for people by forging meaningful relationships with them.
I treat each patient as a partner, and together, we work toward a common goal. Communication with my patients and their caregivers is essential to providing the best care. I also prioritize providing my patients with access to clinical trials.
At Perlmutter Cancer Center, my colleagues and I approach cancer treatment as a collaboration between specialties. We offer patients the most current clinical trials and we strive to provide as much support as possible for patients and families during such a difficult time.
My clinical and research interest is gastrointestinal cancers, with a focus on liver and biliary cancer, pancreatic cancer, and gastric cancer. Currently, I am studying whether radiation therapy in combination with immunotherapy is an effective treatment for pancreatic cancer.
Conditions and Treatments
Show More Conditions
Learn more about conditions we treat at NYU Langone:
Colorectal Cancer, Liver & Bile Duct Cancers, Small Intestine Cancer, Stomach Cancer, Pancreatic Cancer, Esophageal CancerCredentials
Positions
- Associate Professor, Department of Medicine
- Section Chief, Hematology and Medical Oncology, Bellevue Hospital
- Director, Bellevue Cancer Center
Board Certifications
- American Board of Internal Medicine (Hematology), 2007
- American Board of Internal Medicine (Medical Oncology), 2006
- American Board of Internal Medicine - Internal Medicine, 2003
Education and Training
- Fellowship, NYU Medical Center, Hematology/Oncology, 2006
- Fellowship, NYU Medical Center, Hematology/Oncology, 2004
- MD from Albert Einstein College of Med, 2000
Departments
Is this your profile?
Edit profileIs this your profile?
Edit profileClinical Trials and Research Studies
-
Learn More
A Phase 3 Randomized Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation
-
Learn More
A PHASE l/ll OPEN LABEL MULTI-CENTER STUDY OF IMMUNE CHECKPOINT THERAPY WITH NIVOLUMAB FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA
-
Learn More
TAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
Publications
-
Boland, Patrick; Wu, Jennifer
Chinese clinical oncology. 2018 Oct ; 7(5):50
-
Contratto, Merly; Wu, Jennifer
World journal of gastrointestinal oncology. 2018 May 15; 10(5):108-114
-
Kwa, Maryann; Li, Xiaochun; Novik, Yelena; Oratz, Ruth; Jhaveri, Komal; Wu, Jennifer; Gu, Ping; Meyers, Marleen; Muggia, Franco; Speyer, James; Iwano, Alyssa; Bonakdar, Maryam; Kozhaya, Lina; Tavukcuoglu, Ece; Budan, Bahar; Raad, Roy; Goldberg, Judith D; Unutmaz, Derya; Adams, Sylvia
Breast cancer research & treatment. 2018 Feb ; 168(1):57-67